Inframe insertions of three or more base pairs in exon 20 of the epidermal growth factor receptor (gene were among the firstmutations to be identified as oncogenic drivers in non-small cell lung cancer (NSCLC). However, unlike the classicalL858R point mutation or exon 19 deletions, which ...
[1] Kwon CS, Lin HM, Crossland V, et al. Non-small cell lung cancer with EGFR exon 20 insertion mutation: a systematic literature review and meta-analysis of patient outcomes. Curr Med Res Opin. 2022 Aug;38(8)...
3.Yasuda H, Ichihara E, Sakakibara-Konishi J, et al. A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer. Lung Cancer. 2021;162:140-146. doi:10.1016/j.lungcan.2021.10.006. 4.Girard N. WCLC 2020. Abstract MA04.07. 5.Yang G, Li...
the most common EGFRex20ins mutation (A767_V769dup) and co-mutation (TP53), as well as clinical characteristics of EGFRex20ins in Chinese NSCLC patients. As for six EGFRex20ins positive patients with osimertinib treatment, four
Meanwhile, myelosuppres- sion is also found in the patient, which requires attention to pulmonary symptoms and careful monitoring.Keywords Lung adenocarcinoma, HER2 exon 20 insertion mutation, T-DM1, DS-8201, Myelosuppression 展开 关键词: Lung adenocarcinoma HER2 exon 20 insertion mutation T-DM1 ...
《柳叶刀·呼吸医学》(The Lancet Respiratory Medicine,IF=76.2)发表题为“Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial”的...
[2]中国临床肿瘤学会非小细胞肺癌专家委员会,EGFR 20外显子插入突变非小细胞肺癌规范化诊疗中国专家共识(2023版). [3]Wang Y, Chu T. [Progress in Detection of EGFR Exon 20 Insertion Mutation and Targeted Therapies in Non...
[3]Wang Y, Chu T. [Progress in Detection of EGFR Exon 20 Insertion Mutation and Targeted Therapies in Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi. 2023 Feb 20;26(2):135-147. Chinese. doi: 10.3779/j.issn.1009-3419.2023.102.06. PMID: 36872052; PMCID: PMC10033239. ...
Metro 等的研究结果显示,接受免疫治疗的 EGFR ex20ins 突变型晚期 NSCLC 患者中位 PFS 为 2 个月,中位 OS 为 5.3 个月,免疫治疗的效果欠佳。推测其原因可能是由于 EGFR ex20ins 突变型 NSCLC 患者的肿瘤突变负荷(tumor mutation burden,TMB)显著低于非 EGFR ex20ins 突变型 NSCLC 患者,且 EGFR ex20ins ...
A phase 2 study of poziotinib in patients with EGFR or HER2 exon 20 mutation-positive non-small cell lung cancer 来自 Semantic Scholar 喜欢 0 阅读量: 96 作者:Z Yang,N Tchekmedyian,DT Chu,G Reddy,MA Socinski 摘要: TPS9106Background: Poziotinib is a novel, oral, quinazoline-based ...